Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SNTI |
---|---|---|
09:43 ET | 2001 | 0.3832 |
09:48 ET | 3265 | 0.38 |
09:56 ET | 594 | 0.3801 |
09:59 ET | 11827 | 0.38 |
10:28 ET | 20895 | 0.36 |
10:30 ET | 1500 | 0.36001 |
10:44 ET | 22631 | 0.36 |
10:55 ET | 2101 | 0.37 |
11:56 ET | 500 | 0.387 |
12:18 ET | 250 | 0.3931 |
12:57 ET | 3500 | 0.374101 |
02:15 ET | 168 | 0.3829 |
02:45 ET | 900 | 0.3741 |
02:47 ET | 250 | 0.375 |
03:23 ET | 2067 | 0.39 |
03:27 ET | 9050 | 0.39 |
03:32 ET | 13902 | 0.374 |
03:38 ET | 3056 | 0.3733 |
03:43 ET | 100 | 0.3763 |
03:48 ET | 200 | 0.388 |
03:57 ET | 237 | 0.3878 |
03:59 ET | 400 | 0.3771 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Senti Biosciences Inc | 17.3M | -0.2x | --- |
Synlogic Inc | 20.8M | -0.2x | --- |
Lumos Pharma Inc | 22.9M | -0.7x | --- |
Addex Therapeutics Ltd | 19.5M | 0.0x | --- |
OpGen Inc | 7.0M | -0.1x | --- |
Xenetic Biosciences Inc | 5.8M | -1.4x | --- |
Senti Biosciences, Inc. is a clinical-stage biotechnology company. It is developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. It is focused on off-the-shelf CAR-NK cell therapy programs for oncology indications. Its lead product candidate, SENTI-202, is a potential Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia, while sparing healthy bone marrow cells. Its second clinical development program is SENTI-301A, a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy. SENTI-202 has been designed to incorporate three chimeric proteins using a Logic Gated gene circuit and delivered through a single retrovirus. SENTI-301A is a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy designed for the treatment of advanced GPC3 positive tumors.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $17.3M |
---|---|
Revenue (TTM) | $2.6M |
Shares Outstanding | 45.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.09 |
Book Value | $1.46 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 6.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,984.50% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.